Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

BACKGROUND: Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis. In the TAGS study, trifluridine/tipiracil (FTD/TPI) improved overall survival (OS) compared with placebo in heavily pre-treated patients. This unplanned, explorator...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253956/
https://www.ncbi.nlm.nih.gov/pubmed/34175675
http://dx.doi.org/10.1016/j.esmoop.2021.100200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253956/
https://www.ncbi.nlm.nih.gov/pubmed/34175675
http://dx.doi.org/10.1016/j.esmoop.2021.100200

Ejemplares similares